Proteomics: Technologies and Global Markets

  • May 2013
  • -
  • BCC Research
  • -
  • 163 pages

STUDY GOALS AND OBJECTIVES

BCC Research’s goal for this study was to determine the status of proteomic technologies and products and assess their global growth potential over the five-year period from 2012 to 2017. The market was analyzed for the main proteomic platforms: mass spectrometry and biochips.

The biochip market was characterized by key biochip type (i.e., lab-on-a-chip, planar array, bead array) and by end-use industry (e.g., research, drug discovery and development, diagnostics, applied).

The mass spectrometry (MS) market was characterized by MS instrument type and end-use industry, as well as by MS workflow (e.g., sample preparation, chromatography, tagging and labeling reagents, and informatics).

A particular focus of the study is placed on the market for proteomic-based diagnostics products, which highlights a major future market segment for proteomic technologies.

The key objective was to present a comprehensive discussion of the main commercial proteomic technologies, along with the current and future commercial potential for each of the key market segments.

REASONS FOR DOING THE STUDY

BCC Research has previously examined the proteomic industry as part of several larger studies. For example, BCC published a report on biochips in 2011 that covered protein arrays and lab-on-a-chip (LOAC) products and markets. In 2010, BCC published a report on next-generation cancer diagnostics that covered diagnostics applications for proteomic biochips.

The main objective for the present report is to present the up-to-date market picture for proteomics into a single comprehensive report. The objective was to capture the changing industry dynamics and market shift occurring in this industry. Thus, it is timely to examine the key aspects of the proteomic industry.

There is also an urgent need in the life science industry for technologies and products that can analyze and study the human proteome in a high-throughput, multiplex and low-cost way. Proteomic technologies are evolving to meet more of these needs, so it is important to keep abreast of these dynamics.

This report is intended to inform companies in the life science industries regarding the important trends in MS, LOAC and arrays, as well as to provide detailed information concerning the individual market segments and industry dynamics.

CONTRIBUTION OF THE STUDY AND INTENDED AUDIENCE

BCC has compiled a study of critical proteomic technologies that are used in the four major end-user segments: research, drug discovery and development, diagnostics and applied markets. The report discusses the proteomic platforms, market growth driving forces, product types, key market applications, companies and alliances, industry dynamics, patents, future market potential and product sales forecasts for the period from 2012 through 2017.

This study will be of particular interest to the companies in such industries as diagnostics, pharmaceuticals, biotechnology, nanotechnology, life sciences tools, biodefense, medical devices, analytical instruments, chromatography, chemicals, polymers, glass and bioinformatics. It will also be of interest to companies involved in drug, diagnostic and/or biomarker discovery programs; manufacturers of microarrays and lab-on-a-chip devices; sample prep suppliers; bioinformatics developers; and cancer researchers and clinicians.

SCOPE AND FORMAT

The study scope covers MS instruments, consumables, workflow products, planar arrays, bead arrays and LOAC. It also covers the research, drug discovery and development, diagnostics and applied end-user market segments. The main geographical markets—North America, Europe, Japan and Rest of World (ROW)—are included.

The MS market is covered by instrument type, MS consumables, product type and end-user markets. The biochip market is covered by biochip type and the-end user market for each type. The diagnostics market is covered in some detail, including by major platform (i.e., MS, biochips), by disease type and for cancer by indication.

This report provides the current market sizes for these segments, as well as their forecasted growth through 2017.

Technology status and market driving forces are discussed. Factors that influence each market are also discussed, including growth-driving forces, industry alliances and acquisitions, applications in diagnostics and drug discovery, customer needs and competitive trends.

Key industry acquisitions and strategic alliances are given for the three-year period from 2010 through 2012.

This report also examines the main patent trends within the industry and profiles 83 companies.

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study. BCC Research examines the key end-user market segments that will be commercially important during the next five years:

• Research tools.
• Drug discovery and development.
• Diagnostics.
• Applied markets (e.g., forensics, agriculture, environmental).

Based on this analysis, the potential applications of proteomic technologies in each of the major market segments were evaluated, and sales revenues were forecast for the period from 2012 through 2017.
Based on the analysis of both secondary and primary market sources, as well as the key trends in the industry, current and projected market sizes are provided for the various proteomic segments for 2011, 2012 and 2017.

INFORMATION SOURCES

Primary sources for this report included key industry companies and leading research institutions. Data were also compiled from secondary sources, including company websites and industry, trade and government publications.

ANALYST'S CREDENTIALS

John Bergin has written previous BCC Research biotechnology reports, including Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics; Global Biochip Markets: Microarrays and Lab-on-a-chip; RNA Interference in the Post-Genomic Era: Markets and Technologies; DNA Sequencing: Emerging Technologies and Applications; Biologic Imaging Reagents: Technologies and Global Markets; and Synthetic Biology: Emerging Global Markets. Mr. Bergin has held business development, sales and marketing positions with a Fortune 500 advanced materials company, as well as executive management positions with an emerging nanotechnology company. Mr. Bergin holds a BS in Chemistry, an MS in Biotechnology and a Masters of Business Administration.

REPORT HIGHLIGHTS

This report provides:

• An overview of the global proteomics market, which covers: technologies, database and software markets, equipment markets, application markets and service markets.
• Analyses of global market trends, with data from 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017.
• Discussion of trends and opportunities, top-selling products, key players, and a competitive outlook.
• Comprehensive company profiles across subsegments, such as protein chip providers, reagent providers, service providers, informatics and database providers, etc.

Table Of Contents

TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION 2

STUDY GOALS AND OBJECTIVES 2
REASONS FOR DOING THE STUDY 2
CONTRIBUTION OF THE STUDY AND INTENDED AUDIENCE 3
SCOPE AND FORMAT 3
METHODOLOGY 3
INFORMATION SOURCES 4
ANALYST'S CREDENTIALS 4
RELATED BCC REPORTS 4
BCC ONLINE SERVICES 5
DISCLAIMER 5

CHAPTER 2 SUMMARY 7

SUMMARY TABLE GLOBAL PROTEOMIC MARKET BY END-USE INDUSTRY, THROUGH
2017 ($ MILLIONS) 7
SUMMARY FIGURE GLOBAL PROTEOMIC MARKET BY END-USE INDUSTRY,
THROUGH 2017 ($ MILLIONS) 7

CHAPTER 3 OVERVIEW 10

PROTEOMIC TECHNOLOGIES 10
TABLE 1 ARRAY VERSUS LOAC BIOCHIPS 11
TABLE 2 SCOPE OF REPORT 12
PROTEOMIC MARKET 12
TABLE 3 GLOBAL PROTEOMIC MARKET BY END-USE INDUSTRY, THROUGH 2017 ($
MILLIONS) 13
TABLE 4 GLOBAL PROTEOMIC MARKET BY PLATFORM, THROUGH 2017 ($ MILLIONS) 14
DRIVING FORCES FOR PROTEOMIC INDUSTRY GROWTH 15
TABLE 5 PROTEOMIC INDUSTRY GROWTH DRIVERS 15
PROTEOMIC INDUSTRY 16
TABLE 6 BIOCHIP INDUSTRY COMPARISONS 16

CHAPTER 4 PROTEOMIC TECHNOLOGIES 19

INTRODUCTION TO TECHNOLOGY PLATFORMS 19
FIGURE 1 MASS SPECTROMETRY-BASED PROTEOMIC WORKFLOW 19
FIGURE 2 PROTEOMIC BIOCHIP AND ARRAY FORMATS 21
MASS SPECTROMETRY-BASED PROTEOMIC TECHNOLOGIES 22
SAMPLE PREPARATION ASSAYS 22
TAGGING AND AFFINITY METHODS 23
MASS SPECTROMETRY INSTRUMENTS AND CONSUMABLES 23
TABLE 7 MASS SPECTROMETER PLATFORMS 25
BIOCHIP-BASED PROTEOMIC TECHNOLOGIES 25
TABLE 8 BIOCHIP-BASED PROTEOMIC TECHNOLOGIES 25
TABLE 9 PLANAR-BASED VERSUS BEAD-BASED ARRAYS 26
ADVANCES IN PROTEOMIC TECHNOLOGIES 27
TABLE 10 TECHNICAL ADVANCES IN PROTEOMICS 27

CHAPTER 5 PROTEOMIC APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT 30

TABLE 11 PROTEOMIC APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT 30
TARGET DISCOVERY 30
LEAD IDENTIFICATION 32
LEAD OPTIMIZATION 33
PRECLINICAL STUDIES 33

CHAPTER 6 PROTEOMIC SCIENTIFIC INITIATIVES 35

TABLE 12 LARGE-SCALE PROTEOMIC INITIATIVES 35

CHAPTER 7 CLINICAL PROTEOMIC APPLICATIONS 39

TABLE 13 STRATEGIES FOR OVERCOMING HIGH-ABUNDANCE PROTEINS IN
CLINICAL SAMPLES 39
CANCER APPLICATIONS 40
CANCER OVERVIEW 40
TABLE 14 U.S. INCIDENCE OF SELECTED CANCERS, 2010 40
BLADDER CANCER 41
TABLE 15 STATUS OF ADVANCED BLADDER CANCER DIAGNOSTICS 41
BREAST CANCER 43
Breast Cancer Screening 43
Prognosis and Pharmacogenetics Tests 43
TABLE 16 U.S. ANNUAL BREAST CANCER TREATMENT DECISIONS BY
CLASSIFICATION 44
Breast Cancer MDx Platforms 45
TABLE 17 BREAST CANCER MDX TECHNOLOGY PLATFORMS 45
TABLE 18 STATUS OF ADVANCED BREAST CANCER DIAGNOSTICS 46
LUNG CANCER 50
TABLE 19 FIVE-YEAR SURVIVAL RATES FOR NON-SMALL-CELL LUNG CANCER (%) 50
TABLE 20 STATUS OF ADVANCED LUNG CANCER DIAGNOSTICS 51
OVARIAN CANCER 55
TABLE 21 EARLY SCREENING OVARIAN CANCER TESTS 55
TABLE 22 STATUS OF ADVANCED OVARIAN CANCER DIAGNOSTICS 56
PROSTATE CANCER 58
TABLE 23 STATUS OF ADVANCED PROSTATE CANCER DIAGNOSTICS 59
THYROID CANCER 62
GENERAL CANCER 62
INFECTIOUS DISEASE APPLICATIONS 62
NEUROLOGICAL APPLICATIONS 63
ALZHEIMER'S DISEASE 63
TABLE 24 ALZHEIMER'S DISEASE DIAGNOSTIC APPROACHES 63
TABLE 25 STATUS OF ALZHEIMER'S DISEASE ADVANCED DIAGNOSTIC TESTS 64
SCHIZOPHRENIA 65
IMMUNE DISEASE APPLICATIONS 66
HUMAN LEUKOCYTE ANTIGEN TYPING TESTS 66
TABLE 26 HUMAN LEUKOCYTE ANTIGEN TESTING MARKET 67
ALLERGY AND AUTOIMMUNE DISEASE 69

CHAPTER 8 PROTEOMIC INDUSTRY 71

INDUSTRY ACQUISITIONS 71
TABLE 27 PROTEOMIC INDUSTRY ACQUISITIONS, 2010-2012 71
INDUSTRY STRATEGIC ALLIANCES 73
TABLE 28 STRATEGIC ALLIANCES IN THE PROTEOMIC INDUSTRY, 2010-2012 73
MASS SPECTROMETRY INDUSTRY 77
TABLE 29 FIRST-TIER MASS SPECTROMETRY COMPANIES 77
TABLE 30 SECOND-TIER MASS SPECTROMETRY COMPANIES 78
PROTEOMIC CHROMATOGRAPHY INDUSTRY 79
FIGURE 3 CHROMATOGRAPHY RESINS IN MS WORKFLOW 79
TABLE 31 GLOBAL HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY COLUMN
MANUFACTURING COMPANIES 80
TABLE 32 JAPANESE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY COLUMN
LEADING MANUFACTURING COMPANIES 81
PROTEOMIC-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 82
TABLE 33 GLOBAL PHARMACEUTICAL RESEARCH AND DEVELOPMENT
OUTSOURCING ($ BILLIONS) 82
TABLE 34 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY 83
PROTEOMIC BIOCHIP INDUSTRY 84
PEPTIDE MICROARRAY INDUSTRY 84
TABLE 35 KEY PEPTIDE MICROARRAY COMPANIES 85
ANTIBODY MICROARRAY INDUSTRY 86
TABLE 36 KEY ANTIBODY MICROARRAY COMPANIES 86
CHINA BIOCHIP INDUSTRY 87
TABLE 37 CHINESE BIOCHIP INDUSTRY 88
LAB-ON-A-CHIP PROTEOMIC INDUSTRY 89
TABLE 38 LAB-ON-A-CHIP COMPETITOR LANDSCAPE 90
ANTIBODY REAGENT INDUSTRY 91
TABLE 39 ANTIBODY REAGENT MARKET, 2012 (%) 92
MULTIPLEX PROTEIN DIAGNOSTICS INDUSTRY 92
TABLE 40 MULTIPLEX PROTEIN IN VITRO DIAGNOSTIC COMPANIES 93

CHAPTER 9 PROTEOMIC MARKETS 97

DRIVING FORCES OF PROTEOMIC INDUSTRY GROWTH 97
TABLE 41 PROTEOMIC INDUSTRY GROWTH DRIVERS 97
GLOBAL PROTEOMIC MARKETS 98
PROTEOMIC MARKET SUMMARY 98
TABLE 42 GLOBAL PROTEOMIC MARKET BY PLATFORM, THROUGH 2017 ($
MILLIONS) 98
TABLE 43 GLOBAL PROTEOMIC MARKET BY END-USE INDUSTRY, THROUGH 2017 ($
MILLIONS) 99
PROTEOMIC RESEARCH MARKETS 101
TABLE 44 GLOBAL PROTEOMIC RESEARCH PRODUCT MARKET BY PLATFORM,
THROUGH 2017 ($ MILLIONS) 102
TABLE 45 GLOBAL PROTEOMIC RESEARCH MARKET BY BIOCHIP PLATFORM,
THROUGH 2017 ($ MILLIONS) 102
PROTEOMIC DRUG DISCOVERY AND DEVELOPMENT MARKETS 103
TABLE 46 GLOBAL PROTEOMIC DRUG DISCOVERY AND DEVELOPMENT PRODUCT
MARKET BY PLATFORM, THROUGH 2017 ($ MILLIONS) 103
TABLE 47 GLOBAL PROTEOMIC DRUG DISCOVERY AND DEVELOPMENT BIOCHIP
MARKET BY PLATFORM, THROUGH 2017 ($ MILLIONS) 104
PROTEOMIC DIAGNOSTIC MARKETS 105
TABLE 48 GLOBAL PROTEOMIC DIAGNOSTIC PRODUCT MARKET BY PLATFORM,
THROUGH 2017 ($ MILLIONS) 105
TABLE 49 GLOBAL BIOCHIP DIAGNOSTIC MARKET BY TYPE, THROUGH 2017 ($
MILLIONS) 106
TABLE 50 GLOBAL PROTEOMIC DIAGNOSTIC PRODUCT MARKET BY DISEASE TYPE,
THROUGH 2017 ($ MILLIONS) 108
TABLE 51 STATUS OF PROTEOMIC-BASED DIAGNOSTICS FOR CARDIOLOGY,
IMMUNE SYSTEM AND NEUROLOGY APPLICATIONS 109
TABLE 52 GLOBAL PROTEOMIC CANCER DIAGNOSTIC PRODUCT MARKET BY
INDICATION, THROUGH 2017 ($ MILLIONS) 110
TABLE 53 STATUS OF PROTEOMIC-BASED DIAGNOSTICS FOR CANCER
APPLICATIONS 111
MASS SPECTROMETRY-BASED PROTEOMIC MARKETS 112
TABLE 54 GLOBAL MASS SPECTROMETRY MARKET BY PRODUCT TYPE, THROUGH
2017 ($ MILLIONS) 112
TABLE 55 GLOBAL MASS SPECTROMETRY MARKET BY END USER INDUSTRY,
THROUGH 2017 ($ MILLIONS) 113
TABLE 56 GLOBAL MASS SPECTROMETRY INSTRUMENT MARKET BY TECHNIQUE,
THROUGH 2017 ($ MILLIONS) 115
TABLE 57 GLOBAL MASS SPECTROMETRY CONSUMABLE MARKET BY TYPE,
THROUGH 2017 ($ MILLIONS) 116
BIOCHIP-BASED PROTEOMIC MARKETS 117
TABLE 58 GLOBAL PROTEOMIC BIOCHIP MARKET BY TYPE, THROUGH 2017 ($
MILLIONS) 117
TABLE 59 GLOBAL PROTEOMIC ARRAY MARKET BY TYPE, THROUGH 2017 ($
MILLIONS) 118
TABLE 60 GLOBAL PROTEOMIC BIOCHIP MARKET BY END USER, THROUGH 2017 ($
MILLIONS) 118
TABLE 61 GLOBAL PROTEOMIC ARRAY MARKET BY END USE, THROUGH 2017 ($
MILLIONS) 119
TABLE 62 GLOBAL PROTEOMIC LAB-ON-A-CHIP MARKET BY END USE, THROUGH
2017 ($ MILLIONS) 121
PROTEOMIC GEOGRAPHIC MARKETS 124
TABLE 63 GLOBAL PROTEOMIC MARKET BY REGION, THROUGH 2017 ($ MILLIONS) 124
TABLE 64 GLOBAL PROTEOMIC DIAGNOSTIC MARKET BY REGION, THROUGH 2017
($ MILLIONS) 125

CHAPTER 10 PROTEOMIC PATENTS 127

BIOCHIP PATENTS 127
PROTEIN ARRAY PATENTS 127
TABLE 65 ARRAY-RELATED PROTEOMIC PATENTS BY REGION, 2002-2012 127
LAB-ON-A-CHIP PATENTS 128
TABLE 66 LAB-ON-A-CHIP-RELATED PROTEOMIC PATENTS BY REGION, 2002-2012 128
MASS SPECTROMETRY PATENTS 128
TABLE 67 MASS SPECTROMETRY-RELATED PROTEOMIC PATENTS BY REGION,
2002-2012 129

CHAPTER 11 COMPANY PROFILES 131

ABLYNX NV 131
ACTIVIOMICS LTD. 131
ACTIVX BIOSCIENCES INC. 132
ADNEXUS THERAPEUTICS 132
ADVANCED PROTEOME THERAPEUTICS INC. 132
AGILENT TECHNOLOGIES INC. 133
APPLIED PROTEOMICS 134
AYOXXA BIOSYSTEMS GMBH 134
BIODESIX 135
BIOGNOSYS AG 136
BIOPROXIMITY LLC 136
BIO-RAD LABORATORIES INC. 137
BIOSYSTEMS INTERNATIONAL SAS 137
BRUKER CORPORATION 138
CALIBRANT BIOSYSTEMS INC. 138
CAMBRIDGE PROTEIN ARRAYS LTD. 139
CAPRION PROTEOMICS 139
CAPROTEC BIOANALYTICS GMBH 140
CRELUX GMBH 140
CRYSTALGENOMICS INC. 141
DANAHER CORP. 142
DIASSESS 142
DIGILAB INC. 143
DNANO SYSTEMS LLC 143
DURIN TECHNOLOGIES INC. 144
DVS SCIENCES INC. 144
EVOTEC AG 144
GENERAL ELECTRIC CO. 145
GLAXOSMITHKLINE PLC 145
GL SCIENCES INC. 146
GWC TECHNOLOGIES 146
IMMUNOVIA AB 147
IMTAKT CORPORATION 147
INTEGRATED DIAGNOSTICS 148
IRIS INTERNATIONAL INC. 148
LEAP TECHNOLOGIES INC. 149
LIFE TECHNOLOGIES INC. 149
LUMINEX CORPORATION 150
MERCK KGAA 150
MICROLYTIC APS 151
MRM PROTEOMICS INC. 151
MOSAIQUES DIAGNOSTICS AND THERAPEUTICS AG 152
MYRIAD GENETICS INC. 152
NEXTGEN SCIENCES INC. 152
OLINK BIOSCIENCE 153
ONCOPLEX DX 153
OPKO HEALTH INC. 154
PERKIN ELMER INC. 154
PFIZER INC. 155
PHENOMENEX 156
PHYLOGICA LTD. 156
PRESSURE BIOSCIENCES INC. 157
PRONOTA NV 157
PROTEA BIOSCIENCES INC. 158
PROTEOME SCIENCES 159
PROTEOMICS INTERNATIONAL PTY LTD 159
PROVISTA DIAGNOSTICS INC. 160
QIAGEN NV 160
QUANTERIX INC. 161
QUEST DIAGNOSTICS INC. 161
REPLIGEN CORPORATION 162
SAMDI TECH INC. 162
SHIMADZU CORPORATION 163
SHISEIDO COMPANY LTD. 163
SHOWA DENKO KK 164
SIGMA ALDRICH 164
SINGULEX INC. 165
SISCAPA ASSAY TECHNOLOGIES 165
SOMALOGIC INC. 165
TABLE 68 SOMALOGIC PROTEOMIC METHODS 166
SPHERE FLUIDICS LTD. 166
SPOTON CLINICAL DIAGNOSTICS LTD. 167
SYNAGEVA BIOPHARMA 167
TALKING20 INC. 168
TABLE 69 PERSONALIZED PROTEOMIC COMPANIES 168
THERANOSTICS HEALTH 169
THERMO FISHER SCIENTIFIC INC. 169
TABLE 70 THERMO FISHER SCIENTIFIC RECENT ACQUISITIONS 170
THORNE DIAGNOSTICS INC. 171
TOSOH CORPORATION 171
UNIVERSAL BIOSENSORS LTD. 171
TABLE 71 UNIVERSAL BIOSENSORS DIAGNOSTIC PIPELINE 171
VERMILLION INC. 172
VIRAL GENETICS INC. 173
WATERS CORP. 173
XENCOR INC. 174
YMC CO. LTD. 174



LIST OF TABLES

SUMMARY TABLE GLOBAL PROTEOMIC MARKET BY END-USE INDUSTRY, THROUGH
2017 ($ MILLIONS) 7
TABLE 1 ARRAY VERSUS LOAC BIOCHIPS 11
TABLE 2 SCOPE OF REPORT 12
TABLE 3 GLOBAL PROTEOMIC MARKET BY END-USE INDUSTRY, THROUGH 2017 ($
MILLIONS) 13
TABLE 4 GLOBAL PROTEOMIC MARKET BY PLATFORM, THROUGH 2017 ($ MILLIONS) 14
TABLE 5 PROTEOMIC INDUSTRY GROWTH DRIVERS 15
TABLE 6 BIOCHIP INDUSTRY COMPARISONS 16
TABLE 7 MASS SPECTROMETER PLATFORMS 25
TABLE 8 BIOCHIP-BASED PROTEOMIC TECHNOLOGIES 25
TABLE 9 PLANAR-BASED VERSUS BEAD-BASED ARRAYS 26
TABLE 10 TECHNICAL ADVANCES IN PROTEOMICS 27
TABLE 11 PROTEOMIC APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT 30
TABLE 12 LARGE-SCALE PROTEOMIC INITIATIVES 35
TABLE 13 STRATEGIES FOR OVERCOMING HIGH-ABUNDANCE PROTEINS IN CLINICAL
SAMPLES 39
TABLE 14 U.S. INCIDENCE OF SELECTED CANCERS, 2010 40
TABLE 15 STATUS OF ADVANCED BLADDER CANCER DIAGNOSTICS 41
TABLE 16 U.S. ANNUAL BREAST CANCER TREATMENT DECISIONS BY
CLASSIFICATION 44
TABLE 17 BREAST CANCER MDX TECHNOLOGY PLATFORMS 45
TABLE 18 STATUS OF ADVANCED BREAST CANCER DIAGNOSTICS 46
TABLE 19 FIVE-YEAR SURVIVAL RATES FOR NON-SMALL-CELL LUNG CANCER (%) 50
TABLE 20 STATUS OF ADVANCED LUNG CANCER DIAGNOSTICS 51
TABLE 21 EARLY SCREENING OVARIAN CANCER TESTS 55
TABLE 22 STATUS OF ADVANCED OVARIAN CANCER DIAGNOSTICS 56
TABLE 23 STATUS OF ADVANCED PROSTATE CANCER DIAGNOSTICS 59
TABLE 24 ALZHEIMER'S DISEASE DIAGNOSTIC APPROACHES 63
TABLE 25 STATUS OF ALZHEIMER'S DISEASE ADVANCED DIAGNOSTIC TESTS 64
TABLE 26 HUMAN LEUKOCYTE ANTIGEN TESTING MARKET 67
TABLE 27 PROTEOMIC INDUSTRY ACQUISITIONS, 2010-2012 71
TABLE 28 STRATEGIC ALLIANCES IN THE PROTEOMIC INDUSTRY, 2010-2012 73
TABLE 29 FIRST-TIER MASS SPECTROMETRY COMPANIES 77
TABLE 30 SECOND-TIER MASS SPECTROMETRY COMPANIES 78
TABLE 31 GLOBAL HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY COLUMN
MANUFACTURING COMPANIES 80
TABLE 32 JAPANESE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY COLUMN
LEADING MANUFACTURING COMPANIES 81
TABLE 33 GLOBAL PHARMACEUTICAL RESEARCH AND DEVELOPMENT
OUTSOURCING ($ BILLIONS) 82
TABLE 34 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY 83
TABLE 35 KEY PEPTIDE MICROARRAY COMPANIES 85
TABLE 36 KEY ANTIBODY MICROARRAY COMPANIES 86
TABLE 37 CHINESE BIOCHIP INDUSTRY 88
TABLE 38 LAB-ON-A-CHIP COMPETITOR LANDSCAPE 90
TABLE 39 ANTIBODY REAGENT MARKET, 2012 (%) 92
TABLE 40 MULTIPLEX PROTEIN IN VITRO DIAGNOSTIC COMPANIES 93
TABLE 41 PROTEOMIC INDUSTRY GROWTH DRIVERS 97
TABLE 42 GLOBAL PROTEOMIC MARKET BY PLATFORM, THROUGH 2017 ($ MILLIONS) 98
TABLE 43 GLOBAL PROTEOMIC MARKET BY END-USE INDUSTRY, THROUGH 2017 ($
MILLIONS) 99
TABLE 44 GLOBAL PROTEOMIC RESEARCH PRODUCT MARKET BY PLATFORM,
THROUGH 2017 ($ MILLIONS) 102
TABLE 45 GLOBAL PROTEOMIC RESEARCH MARKET BY BIOCHIP PLATFORM,
THROUGH 2017 ($ MILLIONS) 102
TABLE 46 GLOBAL PROTEOMIC DRUG DISCOVERY AND DEVELOPMENT PRODUCT
MARKET BY PLATFORM, THROUGH 2017 ($ MILLIONS) 103
TABLE 47 GLOBAL PROTEOMIC DRUG DISCOVERY AND DEVELOPMENT BIOCHIP
MARKET BY PLATFORM, THROUGH 2017 ($ MILLIONS) 104
TABLE 48 GLOBAL PROTEOMIC DIAGNOSTIC PRODUCT MARKET BY PLATFORM,
THROUGH 2017 ($ MILLIONS) 105
TABLE 49 GLOBAL BIOCHIP DIAGNOSTIC MARKET BY TYPE, THROUGH 2017 ($
MILLIONS) 106
TABLE 50 GLOBAL PROTEOMIC DIAGNOSTIC PRODUCT MARKET BY DISEASE TYPE,
THROUGH 2017 ($ MILLIONS) 108
TABLE 51 STATUS OF PROTEOMIC-BASED DIAGNOSTICS FOR CARDIOLOGY, IMMUNE
SYSTEM AND NEUROLOGY APPLICATIONS 109
TABLE 52 GLOBAL PROTEOMIC CANCER DIAGNOSTIC PRODUCT MARKET BY
INDICATION, THROUGH 2017 ($ MILLIONS) 110
TABLE 53 STATUS OF PROTEOMIC-BASED DIAGNOSTICS FOR CANCER APPLICATIONS 111
TABLE 54 GLOBAL MASS SPECTROMETRY MARKET BY PRODUCT TYPE, THROUGH
2017 ($ MILLIONS) 112
TABLE 55 GLOBAL MASS SPECTROMETRY MARKET BY END USER INDUSTRY,
THROUGH 2017 ($ MILLIONS) 113
TABLE 56 GLOBAL MASS SPECTROMETRY INSTRUMENT MARKET BY TECHNIQUE,
THROUGH 2017 ($ MILLIONS) 115
TABLE 57 GLOBAL MASS SPECTROMETRY CONSUMABLE MARKET BY TYPE,
THROUGH 2017 ($ MILLIONS) 116
TABLE 58 GLOBAL PROTEOMIC BIOCHIP MARKET BY TYPE, THROUGH 2017 ($
MILLIONS) 117
TABLE 59 GLOBAL PROTEOMIC ARRAY MARKET BY TYPE, THROUGH 2017 ($
MILLIONS) 118
TABLE 60 GLOBAL PROTEOMIC BIOCHIP MARKET BY END USER, THROUGH 2017 ($
MILLIONS) 118
TABLE 61 GLOBAL PROTEOMIC ARRAY MARKET BY END USE, THROUGH 2017 ($
MILLIONS) 119
TABLE 62 GLOBAL PROTEOMIC LAB-ON-A-CHIP MARKET BY END USE, THROUGH
2017 ($ MILLIONS) 121
TABLE 63 GLOBAL PROTEOMIC MARKET BY REGION, THROUGH 2017 ($ MILLIONS) 124
TABLE 64 GLOBAL PROTEOMIC DIAGNOSTIC MARKET BY REGION, THROUGH 2017 ($
MILLIONS) 125
TABLE 65 ARRAY-RELATED PROTEOMIC PATENTS BY REGION, 2002-2012 127
TABLE 66 LAB-ON-A-CHIP-RELATED PROTEOMIC PATENTS BY REGION, 2002-2012 128
TABLE 67 MASS SPECTROMETRY-RELATED PROTEOMIC PATENTS BY REGION,
2002-2012 129
TABLE 68 SOMALOGIC PROTEOMIC METHODS 166
TABLE 69 PERSONALIZED PROTEOMIC COMPANIES 168
TABLE 70 THERMO FISHER SCIENTIFIC RECENT ACQUISITIONS 170
TABLE 71 UNIVERSAL BIOSENSORS DIAGNOSTIC PIPELINE 171



LIST OF FIGURES

SUMMARY FIGURE GLOBAL PROTEOMIC MARKET BY END-USE INDUSTRY, THROUGH
2017 ($ MILLIONS) 7
FIGURE 1 MASS SPECTROMETRY-BASED PROTEOMIC WORKFLOW 19
FIGURE 2 PROTEOMIC BIOCHIP AND ARRAY FORMATS 21
FIGURE 3 CHROMATOGRAPHY RESINS IN MS WORKFLOW 79

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Global Next-generation Sequencing Trends

Global Next-generation Sequencing Trends

  • $ 12 500
  • Industry report
  • September 2014
  • by Frost & Sullivan

An End-user Perspective The overall research objective was to capture and analyze global next-generation (NGS) sequencing trends and use. Most researchers outsource NGS technologies; however, in-house ...

Global Next-generation Sequencing Market

Global Next-generation Sequencing Market

  • $ 10 000
  • Industry report
  • June 2014
  • by Frost & Sullivan

On the Verge of a Quadrupled Competitor Size and a Clinical Turning Point The total market, as defined by this study, includes next-generation sequencing instruments and reagents. Instruments include those ...

Global Bioinformatics Industry

Global Bioinformatics Industry

  • $ 4 950
  • Industry report
  • July 2014
  • by Global Industry Analysts

This report analyzes the worldwide markets for Bioinformatics in US$ Million by the following Product Segments: Software, Hardware, and Biocontent. The report provides separate comprehensive analytics ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.